专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008110466A1 NITROXIDES FOR LITHIUM-ION BATTERIES 审中-公开
标题翻译：硝酸锂用于锂离子电池
公开(公告)号：WO2008110466A1
公开(公告)日：2008-09-18
申请号：PCT/EP2008/052464
申请日：2008-02-29
申请人： CIBA HOLDING INC. , BUGNON FOLGER, Lucienne , HINTERMANN, Tobias , NESVADBA, Peter , FREY, Markus
发明人： HINTERMANN, Tobias , NESVADBA, Peter , FREY, Markus
IPC分类号： H01M10/40 , C07D233/30 , C07D233/32 , C07D241/08 , C07D265/32 , H01M4/48 , H01M4/50 , H01M4/52 , H01M4/58
CPC分类号： C07D233/32 , C07D233/42 , C07D235/02 , C07D241/08 , C07D241/52 , C07D243/14 , C07D265/32 , C07D265/34 , C07D265/36 , C07D405/06 , C07F9/6584 , H01M10/0525 , H01M10/0567 , H01M10/0568 , H01M10/0569 , H01M10/4235
摘要： This invention relates to overcharge protection and molecular redox shuttles in rechargeable lithium-ion cells. For this, specific nitroxyls or oxoammonium salts are used in the electrolyte. This invention also relates to a method of producing such lithium-ion cells and to a method of recharging such lithium-ion cells. This invention also pertains to some nitroxyls compounds and oxoammonium salts.
摘要翻译：本发明涉及可充电锂离子电池中的过充电保护和分子氧化还原梭。为此，在电解质中使用特定的硝酰氧基或氧代铵盐。本发明还涉及这种锂离子电池的制造方法和锂离子电池的充电方法。本发明还涉及一些硝酰基化合物和氧代铵盐。

2. 发明申请

WO2018069532A1 INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE 审中-公开
标题翻译： α-氨基-β-羧基琥珀酸半醛脱羧酶抑制剂
公开(公告)号：WO2018069532A1
公开(公告)日：2018-04-19
申请号：PCT/EP2017/076252
申请日：2017-10-13
申请人： TES PHARMA S.R.L.
发明人： PELLICCIARI, Roberto
IPC分类号： C07D233/30 , C07D233/32 , C07D233/40 , C07D233/54 , C07D233/70 , C07D233/96
摘要： The present disclosure discloses compounds capable of modulating the activity of α- amino-β-carboxymuconic acid semialdehyde decarboxylase (ACMSD), which are useful for the prevention and/or the treatment of diseases and disorders associated with defects in NAD + biosynthesis, e.g., metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, kidney diseases, and diseases associated with ageing. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
摘要翻译：本公开公开了能够调节α-氨基-β-羧基粘康酸半醛脱羧酶（ACMSD）活性的化合物，其可用于预防和/或治疗与以下疾病和病症有关的疾病和病症 NAD +生物合成中的缺陷，例如代谢紊乱，神经退行性疾病，慢性炎症疾病，肾脏疾病和与衰老相关的疾病。本申请还公开了包含所述化合物的药物组合物以及这些化合物作为药物的用途。

3. 发明申请

WO2010028189A3 COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS 审中-公开
公开(公告)号：WO2010028189A3
公开(公告)日：2010-06-17
申请号：PCT/US2009055947
申请日：2009-09-03
申请人： ARDEA BIOSCIENCES INC , GUNIC ESMIR , GIRARDET JEAN-LUC , PAISNER DAVID A
发明人： GUNIC ESMIR , GIRARDET JEAN-LUC , PAISNER DAVID A
IPC分类号： C07D233/42 , A61K31/44 , A61P3/00 , C07D233/30
CPC分类号： C07D233/84 , C07D233/70 , C07D249/12 , C07D403/12 , C07D405/12
摘要： Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.

4. 发明申请

WO00068204A1 SUBSTITUTED BENZOYL KETONES, METHODS FOR PRODUCING THEM AND THEIR USE AS HERBICIDES 审中-公开
标题翻译：取代的苯甲酰酮，其制造方法相同，它们作为除草剂
公开(公告)号：WO00068204A1
公开(公告)日：2000-11-16
申请号：PCT/EP2000/003712
申请日：2000-04-26
IPC分类号： A01N43/38 , A01N43/40 , A01N43/50 , A01N43/54 , A01N43/58 , A01N43/64 , A01N43/653 , A01N43/76 , A01N43/824 , A01N53/04 , A01P13/00 , C07D209/48 , C07D213/64 , C07D231/20 , C07D233/30 , C07D233/32 , C07D233/70 , C07D235/26 , C07D237/32 , C07D239/10 , C07D249/08 , C07D249/12 , C07D249/14 , C07D253/04 , C07D253/08 , C07D263/22 , C07D263/58 , C07D275/06 , C07D285/12 , C07D285/13 , C07D413/12 , C07D471/04 , C07D487/04 , C07D233/42
CPC分类号： C07D209/48 , A01N43/653 , C07D213/64 , C07D231/20 , C07D233/70 , C07D237/32 , C07D239/10 , C07D249/12 , C07D249/14 , C07D253/04 , C07D263/58 , C07D275/06 , C07D285/13 , C07D471/04 , C07D487/04
摘要： The invention relates to novel substituted benzoyl ketones of formula (I), wherein n represents 0, 1, 2 or 3; A represents a simple bond or alkanediyl (alkylene); R represents hydrogen or optionally substituted alkyl or cycloalkyl; R represents hydrogen, cyano, carbamoyl, halogen, or optionally substituted alkyl, alkoxy, alkoxycarbonyl, alkylthio, alkylsulfinyl or alkylsulfonyl; R represents hydrogen, nitro, cyano, carboxy, carbamoyl, thiocarbamoyl, halogen or optionally substituted alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, dialkylamino or dialkylaminosulfonyl; R represents nitro, cyano, carboxy, carbamoyl, thiocarbamoyl, halogen or optionally substituted alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, dialkylamino or dialkylaminosulfonyl; and Z represents an optionally substituted 4 to 12-membered, saturated or unsaturated, monocyclic or bicyclic, heterocyclic grouping containing 1 to 4 hetero atoms (up to 4 nitrogen atoms and optionally, - alternatively or additionally - an oxygen atom or a sulphur atom, or an SO2 grouping), which also contains one to three oxo-groups (C=O) and/or thioxo-groups (C=S) as constituents of the heterocycle. The invention also relates to methods for producing the inventive substituted benzoyl ketones and to their use as herbicides.
摘要翻译：本发明涉及式（I），其中n为0，1，2或3的新的取代的苯甲酰基的酮; A表示单键或烷二代表（亚烷基）基团; [R <1>代表氢或在每种情况下任选取代的烷基或环烷基; [R <2>是氢，氰基，氨基甲酰基，卤素，或代表各自任选被取代的烷基，烷氧基，烷氧基羰基，烷硫基，烷基亚磺酰基或烷基磺酰基; [R <3>为氢，硝基，氰基，羧基，氨基甲酰基，硫代氨基甲酰基，卤素，或在每种情况下表示任选取代的烷基，烷氧基，烷硫基，烷基亚磺酰基，烷基磺酰基，烷基氨基，二烷基氨基或二烷基氨基磺酰; [R <4>是硝基，氰基，羧基，氨基甲酰基，硫代氨基甲酰基，卤素，或在每种情况下表示任选取代的烷基，烷氧基，烷硫基，烷基亚磺酰基，烷基磺酰基，烷基氨基，二烷基氨基或二烷基氨基磺酰; 和Z是任选取代的4-至12-元饱和或不饱和的，单环或双环的含1至4个杂原子的杂环部分（最多4个氮原子和任选的 - 可替换地或附加地 - 一个氧原子或一个硫原子，或一个含有SO分组或一个SO 2分组），并且其另外一到三个氧代基团（C = O）和/或硫代基团（C = S），作为杂环的组件，以及它们的制备方法和它们的用途包含作为除草剂。

5. 发明申请

WO2012054526A2 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES 审中-公开
标题翻译：化学接受者配体治疗
公开(公告)号：WO2012054526A2
公开(公告)日：2012-04-26
申请号：PCT/US2011056769
申请日：2011-10-18
申请人： ELCELYX THERAPEUTICS INC , BARON ALAIN D , BROWN MARTIN R , JONES CHRISTOPHER R G , BEELEY NIGEL R A
发明人： BARON ALAIN D , BROWN MARTIN R , JONES CHRISTOPHER R G , BEELEY NIGEL R A
IPC分类号： A61K31/4709 , A01N41/10 , A01N43/16 , A01N43/50 , A01P1/00 , A61K31/185 , A61K31/22 , A61K31/7016 , A61K31/7028 , A61K31/704 , A61P31/00 , C07C317/46 , C07D233/30 , C07H7/02
CPC分类号： C07H19/20 , A61K31/165 , A61K31/166 , A61K31/17 , A61K31/216 , A61K31/277 , A61K31/34 , A61K31/36 , A61K31/381 , A61K31/40 , A61K31/4025 , A61K31/4184 , A61K31/4192 , A61K31/42 , A61K31/423 , A61K31/44 , A61K31/4402 , A61K31/443 , A61K31/4433 , A61K31/4436 , A61K31/444 , A61K31/4965 , A61K31/497 , A61K31/505 , A61K31/517 , A61K31/519 , A61K31/549 , A61K31/7068 , A61K31/7076 , A61K45/06 , C07C233/11 , C07C233/51 , C07C233/65 , C07C235/34 , C07C235/46 , C07C235/48 , C07C235/78 , C07C255/57 , C07C275/30 , C07C275/34 , C07C323/62 , C07C2601/14 , C07C2602/10 , C07D213/40 , C07D213/56 , C07D241/24 , C07D285/16 , C07D317/68 , C07D333/24 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D493/04 , C07D495/04 , C07F7/0812 , C07F9/65586 , C07H7/02
摘要： Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.
摘要翻译：本文提供了通过施用包含化学感应受体配体的组合物来治疗与化学感觉受体相关的病症（包括糖尿病，肥胖症和其它代谢疾病，病症或病症）的方法。本文还提供了用于本发明方法的化学感应受体配体组合物及其制备方法。

6. 发明申请

WO2003031414A1 新規なヘテロ環化合物および抗炎症薬审中-公开
标题翻译：新型杂环化合物和抗炎剂
公开(公告)号：WO2003031414A1
公开(公告)日：2003-04-17
申请号：PCT/JP2002/010291
申请日：2002-10-02
申请人：日本曹達株式会社 , 高木眞佐江 , 石光圭一 , 西部忠幸
发明人：高木眞佐江 , 石光圭一 , 西部忠幸
IPC分类号： C07D233/30
CPC分类号： C07D207/277 , A61K31/4166 , A61K31/421 , A61K31/422 , A61K31/426 , A61K31/427 , A61K31/4439 , C07D207/38 , C07D233/30 , C07D233/32 , C07D233/38 , C07D263/16 , C07D263/22 , C07D277/14 , C07D277/16 , C07D405/12 , C07D413/06 , C07D413/10 , C07D413/12 , C07D417/04 , C07D417/06 , C07D417/12
摘要： A compound represented by the formula [I]: [I] (wherein X represents oxygen, sulfur, NR 4 , or CHR 5 ; Y represents oxygen or sulfur; R 1 represents C 1−6 alkyl, etc.; R 2 represents optionally substituted phenyl, etc.; and R 3 represents optionally substituted C 1−6 alkyl, a group represented by any of the following formulae, etc.) [II] or a pharmaceutically acceptable composite of the compound; a medicinal composition containing any of these as an active ingredient; and a use thereof, etc.
摘要翻译：由式[I]表示的化合物：[I]（其中X表示氧，硫，NR 4 S或CHR 5）; Y表示氧或硫; sb> 1 表示C 1-6烷基等; R b'2表示任选取代的苯基等;且R b 3 >表示任选取代的C 1-6烷基，由下式中的任何一个表示的基团等）[II]或该化合物的药学上可接受的复合物; 含有这些作为有效成分的药物组合物; 及其用途等

7. 发明申请

WO01044200A2 SELECTIVE NEUROKININ ANTAGONISTS 审中-公开
标题翻译：选择性神经营养因子拮抗剂
公开(公告)号：WO01044200A2
公开(公告)日：2001-06-21
申请号：PCT/US2000/033831
申请日：2000-12-14
IPC分类号： A61K31/4164 , A61K31/4178 , A61K31/421 , A61K31/433 , A61K31/454 , A61K31/505 , A61K31/506 , A61K31/5377 , A61P1/04 , A61P1/08 , A61P1/14 , A61P3/04 , A61P3/10 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/10 , A61P15/00 , A61P17/06 , A61P19/02 , A61P25/00 , A61P25/06 , A61P25/08 , A61P25/18 , A61P25/22 , A61P25/28 , A61P29/00 , A61P31/04 , A61P37/08 , C07C45/71 , C07C217/46 , C07C217/48 , C07D211/58 , C07D233/14 , C07D233/16 , C07D233/22 , C07D233/30 , C07D233/32 , C07D233/34 , C07D233/40 , C07D233/42 , C07D233/46 , C07D233/48 , C07D233/78 , C07D239/10 , C07D263/24 , C07D285/10 , C07D401/04 , C07D401/12 , C07D403/12 , C07D405/04 , C07D409/06 , C07D413/04 , C07D413/06 , C07D413/10 , C07F9/6506 , A61K31/4166 , A61K31/513 , A61K31/66 , C07D233/26 , C07D233/38 , C07D233/52 , C07D285/06 , C07D403/04 , C07D521/00 , C07F9/22
CPC分类号： C07D239/10 , C07C45/71 , C07C217/48 , C07D211/58 , C07D233/14 , C07D233/16 , C07D233/22 , C07D233/30 , C07D233/32 , C07D233/42 , C07D233/46 , C07D233/48 , C07D233/78 , C07D285/10 , C07D401/04 , C07D401/12 , C07D403/12 , C07D409/06 , C07D413/04 , C07D413/06 , C07D413/10 , C07F9/65061 , C07C47/575
摘要： Compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof, wherein Ar and Ar are optionally substituted heteroaryl or optionally substituted phenyl; X is -O-, -S-, -SO-, -SO2-, -NR -, -NCOR - or -NR SO2R ; (a) is selected from the group consisting of (b), (c), (d) and (e); X is -O-, -S- or -NR -; Y is =O, =S or =NR ; Y is H, C1-C6 alkyl, -NR R , -SCH3, R -aryl(CH2)n6-, R -heteroaryl-(CH2)n6-, -(CH2)n6-heterocycloalkyl, -(C1-C3)alkyl-NH-C(O)O(C1-C6)alkyl or -NHC(O)R ; R is H or -(CH2)n1-G, wherein n1 is 0-5 G is H, -CF3, -CHF2, -CH2F, -OH, -O-(C1-C6 alkyl), -SO2R , -O-(C3-C8 cycloalkyl), -NR R , -SO2NR R , -NR SO2R , -NR COR , -NR (CONR R ), -CONR R , -COOR , C3-C8 cycloalkyl, R -aryl, R -heteroaryl, and provided when n1=0, G is not H; R , R , R and R are H, alkyl, cycloalkyl, -CHF2, -CH2F or -CF3; or R and R , together with the carbon to which they are attached, form an alkylene ring; or R and R together are =O; R is R or -OH; and the remaining variables are as defined in the specifiation, methods of treating diseases susceptible to treatment with neurokinin antagonists with said compounds, and pharmaceutical compositions comprising said compounds are disclosed. Also disclosed are pharmaceutical compositions comprising an effective amount of a compound of claim 1, at least one pharmaceutically acceptable carrier, and in combination with an effective amount of a selective serotonin reuptake inhibitor.
摘要翻译：由结构式（I）表示的化合物或其药学上可接受的盐，其中Ar 1和Ar 2是任选取代的杂芳基或任选取代的苯基; X 1是-O - ， - S - ， - SO - ， - SO 2 - ， - NR 12 - ， - NR C 12 - 或-NR 12 SO 2 R 15。（a）选自（b），（c），（d）和（e）; X 2是-O - ， - S-或-NR 5 - ; Y = O，= S或= NR 11; Y 1是H，C 1 -C 6烷基，-NR 17 R 13，-SCH 3，R 19 - 芳基（CH 2）n6-，R 19 - 杂芳基 - （CH 2）n6-， - （CH 2）n 6-杂环烷基， - （C 1 -C 3）烷基-NH-C（O）O（C 1 -C 6）烷基或-NHC（O）R 15; R 5是H或 - （CH 2）n1-G，其中n1是0-5G是H，-CF3，-CHF2，-CH2F，-OH，-O-（C1-C6烷基），-SO2R 13 C，-O-（C 3 -C 8环烷基），-NR 13 R 14，-SO 2 NR 13 R 14，-NR 13 SO 2 R 15，-NR 13 COR R 12，-NR 12（CONR 13 R 14），-CONR 13 R 14，-COOR 12，C 3 -C 8环烷基，R 19 - 芳基，R 19 当n1 = 0时，G不为H; R 1，R 2，R 3和R 7是H，烷基，环烷基，-CHF 2，-CH 2 F或-CF 3; 或R 1和R 2与它们所连接的碳一起形成亚烷基环; 或R 1和R 2一起为= O; R 6是R 7或-OH; 并且剩余的变量如规定中所定义，治疗易受神经激肽拮抗剂治疗的疾病的方法，以及包含所述化合物的药物组合物。还公开了包含有效量的权利要求1的化合物，至少一种药学上可接受的载体和与有效量的选择性5-羟色胺再摄取抑制剂组合的药物组合物。

8. 发明申请

WO00000476A1 PROCESS FOR PREPARING OXIMIDAZOLES 审中-公开
标题翻译：制备氧化剂的方法
公开(公告)号：WO00000476A1
公开(公告)日：2000-01-06
申请号：PCT/US1999/006912
申请日：1999-03-30
IPC分类号： C07D233/70 , C07D235/02 , C07D233/28 , C07D233/30 , C07D233/32 , C07D403/00
CPC分类号： C07D235/02 , C07D233/70
摘要： A process is disclosed for the preparation of an imidazolone and the pharmaceutically acceptable salts thereof having formula (1). The process comprises treating an alpha -acylaminonitrile of formula (2) with an organic or inorganic acid having the formula HA in a nonaqueous solvent and in the presence of an alcohol of the formula R-OH where R is C5 to C12 alkyl, C5 to C12 alkenyl, C3 to C12 cycloalkyl, poly alkylene ether, poly alkylene thio ether or aryl either unsubstituted or substituted with at least one C1 to C6 alkyl, C1 to C6 alkoxy or halo.
摘要翻译：公开了制备具有式（1）的咪唑啉酮及其药学上可接受的盐的方法。该方法包括用非水溶剂中的式HA的有机或无机酸和式R-OH的醇的存在下将式（2）的α-酰氨基腈处理，其中R为C 5至C 12烷基，C 5至C C12链烯基，C3至C12环烷基，聚亚烷基醚，聚亚烷基硫醚或未被取代或被至少一个C1至C6烷基，C1至C6烷氧基或卤素取代的芳基。

9. 发明申请

WO2010028189A2 COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS 审中-公开
标题翻译：化合物，组合物及使用该组合物调节尿酸水平的方法
公开(公告)号：WO2010028189A2
公开(公告)日：2010-03-11
申请号：PCT/US2009/055947
申请日：2009-09-03
申请人： ARDEA BIOSCIENCES, INC. , GUNIC, Esmir , GIRARDET, Jean-Luc , PAISNER, David A.
发明人： GUNIC, Esmir , GIRARDET, Jean-Luc , PAISNER, David A.
IPC分类号： C07D233/42 , C07D233/30 , A61K31/44 , A61P3/00
CPC分类号： C07D233/84 , C07D233/70 , C07D249/12 , C07D403/12 , C07D405/12
摘要： Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
摘要翻译：本文描述了用于调节血液尿酸水平的化合物，含有它们的制剂以及制备和使用它们的方法。在一些实施方案中，本文所述的化合物用于治疗或预防与异常水平的尿酸有关的病症。

10. 发明申请

WO0012076A9 NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE 审中-公开
标题翻译：硝基和硝基磷酸酯酶抑制剂，组合物和使用方法
公开(公告)号：WO0012076A9
公开(公告)日：2000-08-17
申请号：PCT/US9920024
申请日：1999-09-01
申请人： NITROMED INC , GARVEY DAVID S , SAENZ DE TEJADA INIGO , EARL RICHARD A , KHANAPURE SUBHASH P
发明人： GARVEY DAVID S , SAENZ DE TEJADA INIGO , EARL RICHARD A , KHANAPURE SUBHASH P
IPC分类号： C07D473/30 , A61K31/198 , A61K31/4015 , A61K31/4188 , A61K31/4375 , A61K31/4439 , A61K31/444 , A61K31/445 , A61K31/454 , A61K31/4709 , A61K31/472 , A61K31/4745 , A61K31/4985 , A61K31/50 , A61K31/501 , A61K31/517 , A61K31/519 , A61K31/52 , A61K31/522 , A61K31/7004 , A61K31/7084 , A61K38/00 , A61K45/00 , A61P1/00 , A61P1/18 , A61P9/00 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/02 , A61P13/08 , A61P13/12 , A61P15/00 , A61P15/10 , A61P25/28 , A61P27/16 , A61P29/00 , A61P37/00 , A61P37/08 , A61P43/00 , C07D207/12 , C07D213/89 , C07D215/227 , C07D237/04 , C07D239/95 , C07D277/22 , C07D279/04 , C07D401/02 , C07D401/04 , C07D401/06 , C07D401/10 , C07D403/04 , C07D403/10 , C07D405/14 , C07D471/04 , C07D471/14 , C07D487/04 , C07D487/14 , A61K31/165 , A61K31/38 , A61K31/40 , A61K31/415 , A61K31/425 , A61K31/44 , A61K31/47 , A61K31/505 , C07D207/24 , C07D207/46 , C07D211/72 , C07D211/84 , C07D213/72 , C07D213/75 , C07D213/81 , C07D213/83 , C07D233/28 , C07D233/30 , C07D233/32 , C07D233/38 , C07D279/06 , C07D295/00 , C07D401/00 , C07D417/00 , C07D487/00
CPC分类号： C07D487/04 , C07D405/14
摘要： Disclosed are nitrosated and/or nitrosylated compounds of formulae (I)-(XIX) which are phosphodiesterase inhibitors and compositions comprising them. The invention also provides methods for treating or preventing sexual dysfunctions in males and females and also diseases induced by cGMP.
摘要翻译：公开了作为磷酸二酯酶抑制剂的式（I） - （XIX）的亚硝基化和/或亚硝化化合物及其组成。本发明还提供了治疗或预防男性和女性性功能障碍的方法以及由cGMP引起的疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式